Table 2.
Univariate and Multivariate Cox Regression Analyses of Overall Survival Before Propensity Score Matching
| Variable | Univariable Cox Regression | Multivariable Cox Regression | ||||
|---|---|---|---|---|---|---|
| HR | 95CI | p | HR | 95CI | p | |
| Sex (male/female) | 1.085 | 0.934–1.259 | 0.286 | |||
| Age (≥ 60/< 60 years) | 0.975 | 0.867–1.096 | 0.668 | |||
| HBV (positive/negative) | 0.976 | 0.869–1.095 | 0.678 | |||
| HCV (positive/negative) | 0.551 | 0.319–0.952 | 0.033 | 1.049 | 0.521–1.577 | 0.729 |
| Alcoholism (positive/negative) | 1.129 | 1.003–1.270 | 0.044 | 1.124 | 1.001–1.27 | 0.048 |
| Diabetes mellitus (positive/negative) | 0.999 | 0.824–1.211 | 0.988 | |||
| Hypertension (positive/negative) | 0.823 | 0.698–0.971 | 0.021 | 0.858 | 0.724–1.009 | 0.065 |
| Child–Pugh class (B + C/A) | 2.067 | 1.835–2.327 | < 0.001 | 1.271 | 1.101–1.463 | 0.001 |
| ALBI grade (2+3/1) | 1.573 | 1.374–1.802 | < 0.001 | 0.969 | 0.833–1.132 | 0.708 |
| ALP (≥ 172/< 172 U/L) | 2.673 | 2.380–3.002 | < 0.001 | 1.594 | 1.377–1.820 | < 0.001 |
| LDH (≥ 241/241 U/L) | 1.918 | 1.709–2.153 | < 0.001 | 1.367 | 1.205–1.554 | < 0.001 |
| AFP (≥ 400/< 400 ng/mL) | 1.199 | 1.067–1.347 | 0.002 | 0.925 | 0.819–1.048 | 0.224 |
| Platelet (< 100,000/≥ 100,000/μL) | 1.010 | 0.890–1.147 | 0.873 | |||
| ALT (≥ 40/< 40 U/L) | 1.361 | 1.211–1.529 | < 0.001 | 0.968 | 0.856–1.102 | 0.649 |
| Leukocyte (< 4000/≥ 4000/μL) | 0.885 | 0.759–1.032 | 0.118 | |||
| BCLC stage | <0.001 | <0.001 | ||||
| 0/A | 1.000 | 1.000 | ||||
| B | 1.351 | 1.053–1.732 | 0.018 | 0.982 | 0.740–1.302 | 0.897 |
| C | 2.940 | 2.436–3.547 | < 0.001 | 1.575 | 1.216–2.045 | 0.001 |
| D | 5.643 | 4.062–7.838 | < 0.001 | 1.836 | 1.257–2.675 | 0.002 |
| Number of tumor (≥ 2/< 2) | 1.825 | 1.594–2.090 | < 0.001 | 1.255 | 1.069–1.472 | 0.005 |
| Tumor diameter (≥ 5/< 5 cm) | 1.849 | 1.633–2.094 | < 0.001 | 1.243 | 1.086–1.425 | 0.002 |
| PVTT (positive/negative) | 2.079 | 1.852–2.335 | < 0.001 | 1.140 | 0.990–1.324 | 0.069 |
| Lymph node metastasis (yes/no) | 1.696 | 1.511–1.904 | < 0.001 | 0.912 | 0.787–1.053 | 0.206 |
| Extrahepatic metastases (yes/no) | 1.958 | 1.728–2.219 | < 0.001 | 1.224 | 1.063–1.401 | 0.005 |
| Antitumor therapy | <0.001 | <0.001 | ||||
| Supportive care | 1.000 | 1.000 | ||||
| Liver resection | 0.288 | 0.231–0.359 | <0.001 | 0.463 | 0.368–0.587 | <0.001 |
| RFA | 0.126 | 0.072–0.218 | <0.001 | 0.225 | 0.129–0.397 | <0.001 |
| TACE | 0.580 | 0.502–0.670 | <0.001 | 0.611 | 0.528–0.716 | <0.001 |
| Targeted therapy+ ICI | 0.819 | 0.610–1.101 | 0.186 | 0.794 | 0.593–1.078 | 0.142 |
| Adjuvant TACE | 0.257 | 0.171–0.385 | <0.001 | 0.437 | 0.292–0.666 | <0.001 |
| Other | 0.548 | 0.464–0.647 | <0.001 | 0.610 | 0.518–0.728 | <0.001 |
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; ALBI, albumin–bilirubin; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombus; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; ICI, immune checkpoint inhibitor.